Kezar stock falls 11% after board rejects Concentra offer (update)
Kezar (KZR) stock fell 11% after the company's board rejected an unsolicited takeover offer from Concentra Biosciences and ...
FierceBiotech5d
Kezar rejects Concentra bid that 'substantially undervalues' the biotech
Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra ...
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active ...
GlobalData on MSN4d
Kezar Life Sciences discontinues lupus nephritis programme after fatalities
Kezar’s decision to terminate the PALIZADE IIb trial comes after it was placed on a clinical hold due to four patient deaths.
BioSpace5d
Kezar Cuts Lupus Program After Patient Deaths, Focuses on Autoimmune Hepatitis
Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed ...
Kezar discontinues development of zetomipzomib for lupus nephritis
Kezar (KZR) is discontinuing development of its drug zetomipzomib for the treatment of lupus nephritis so it can focus on ...
Kezar to terminate mid-stage trial for Lupus treatment
The regulator's decision came after the company paused the study in September to review safety data following the deaths of ...
Kezar Life Rejects Proposal From Concentra; Board Adopts Limited Duration Stockholder Rights Plan
Kezar Life Sciences (KZR) announced that its Board has rejected the unsolicited, non-binding proposal from Concentra Biosciences, to ...
Lupus Foundation of America5d
UPDATE: Kezar Life Sciences Terminates Phase 2b Study of Zetomipzomib for Lupus Nephritis Treatment
Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...
Joplin Globe5d
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that ...
Business Wire5d
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in ...